ERBB2 and breast cancer: Here, we adopted two innovative DNA-based technologies, namely molecular inversion probe array analysis (MIP) [21, 22] and next generation sequencing with normalized amplicon coverage analysis (NGS/NAC) [23] for ERBB2 CN assessment in BC.